Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
More about Roivant Sciences
Trailing Twelve Months EPS: ($0.15)
2025 EPS Estimate: ($0.92)
2026 EPS Estimate: ($1.27)
- Current Stock Price
- $9.46
- Consensus Rating
- Buy
- Ratings Breakdown
- 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $17.50 (85.0% Upside)
